Skip to main content

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Estudio doble ciego, aleatorizado y controlado sobre la eficacia de la administración combinada de albúmina y midodrina en la prevención de las complicaciones de pacientes con cirrosis en lista de espera de trasplante hepático

IP: -
Collaborators: Lluis Castells Fusté
Funding agency: Instituto de Salud Carlos III
Funding: 30250
Reference: EC07/90744
Duration: 01/11/2007 - 31/12/2011

Caracterización serológica, inmunologica y molecular de donantes de sangre con infección oculta por virus de la hepatitis B

IP: Silvia Sauleda Oliveras
Collaborators: Lluis Castells Fusté, Marta Bes Maijo, Maria Madeleine Piron
Funding agency: Instituto de Salud Carlos III
Funding: 45980
Reference: PI070754
Duration: 01/01/2008 - 30/12/2010

Selección y expansión de linfocitos CD4+NS3-específicos de pacientes VHC. caracterización del estado de anergia en cronicidad y restauración funcional para empleo en inmunoterapia adaptativa para prevención y tratamiento de la recurrencia postrasplante.

IP: Josep Quer Sivila
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Juan Ignacio Esteban Mur
Funding agency: Instituto de Salud Carlos III
Funding: 113740
Reference: PI061244
Duration: 01/01/2007 - 30/12/2009

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.